Related Experiment Video
Updated: Jan 4, 2026

Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions
Published on: September 22, 2023
The Therapeutic Effect of 1,8-Cineol on Pathogenic Bacteria Species Present in Chronic Rhinosinusitis
Matthias Schürmann1, Felix Oppel1, Martin Gottschalk2
1Department of Otolaryngology, Head and Neck Surgery, Klinikum Bielefeld, Bielefeld, Germany.
Insights
1,8-Cineol effectively inhibits chronic rhinosinusitis (CRS) pathogens and their biofilm formation. This molecule targets key biofilm genes in Staphylococcus aureus, offering a promising new therapeutic avenue for CRS treatment.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Chronic rhinosinusitis (CRS) significantly impairs quality of life due to inflamed sinus mucosa.
- Current CRS treatment lacks specific guidelines, leading to high healthcare costs and persistent symptoms.
- Bacterial infections, microbiome shifts, and biofilm formation are key drivers of CRS progression, complicating antibiotic efficacy.
Purpose of the Study:
- To characterize microbiome alterations in CRS patients.
- To investigate the efficacy of 1,8-Cineol in inhibiting bacterial proliferation and biofilm formation in CRS pathogens.
- To explore the molecular mechanisms underlying 1,8-Cineol's anti-biofilm activity and its effects on host immune response.
Main Methods:
- MALDI-TOF MS used for microbiome profiling in CRS patients and healthy controls.
- In vitro assays to measure bacterial proliferation and biofilm inhibition by 1,8-Cineol.
- RT-qPCR to analyze gene expression related to biofilm formation (agrA, SarA, σB).
- In vitro host models using respiratory epithelium and organotypic slices to assess biofilm inhibition and immune response.
Main Results:
- CRS microbiomes showed a shift towards pathogens like Staphylococcus aureus, Escherichia coli, and Moraxella catarrhalis.
- 1,8-Cineol demonstrated significant inhibition of bacterial proliferation and, notably, biofilm growth for these pathogens.
- Staphylococcus aureus biofilm inhibition by 1,8-Cineol correlated with downregulation of key biofilm genes (agrA, SarA, σB).
- 1,8-Cineol showed efficacy in inhibiting S. aureus biofilms on respiratory epithelium and modulated immune responses in organotypic slice models.
Conclusions:
- 1,8-Cineol is a potent inhibitor of CRS-associated bacterial biofilms, targeting key regulatory genes.
- The study identified specific pathogens in CRS and highlighted 1,8-Cineol's potential as a novel therapeutic agent.
- Developed in vitro models offer a platform for testing 1,8-Cineol and other agents against various bacterial biofilms and host tissues.
Abstract:
Chronic rhinosinusitis (CRS) is marked by an inflamed mucosa of sinuses and is accompanied by a significantly reduced quality of live. Since no guidelines for the treatment of CRS are available, long lasting clinical histories with health care costs adding up to dozens of billion $ annually are caused by CRS. The progression of CRS is often induced by bacterial infections and/or a shift in microbiome as well as biofilm formation. The exact microbiome alterations are still unclear and the impenetrable biofilm renders the treatment with common antibiotics ineffective. This study focuses on characterizing the microbiome changes in CRS and investigating the inhibition of biofilm growth by 1,8-Cineol, a small, non-polar and hence biofilm penetrating molecule with known antimicrobial potential. We performed MALDI-TOF MS based characterization of the microbiomes of healthy individuals and CRS patients (n = 50). The microbiome in our test group was shifted to pathogens (Staphylococcus aureus, Escherichia coli, and Moraxella catarrhalis). In contrast to published studies, solely based on cell culture techniques, we could not verify the abundance of Pseudomonas aeruginosa in CRS. The inhibition of bacterial proliferation and biofilm growth by 1,8-Cineol was measured for these three pathogens. Interestingly, S. aureus, the most prominent germ in CRS, showed a biofilm inhibition not simply correlated to its inhibition of proliferation. RT-qPCR confirmed that this was due to the downregulations of major key players in biofilm generation (agrA, SarA and σB) by 1,8-Cineol. Furthermore we verified this high biofilm inhibition potential in a model host system consisting out of S. aureus biofilm grown on mature respiratory epithelium. A second host model, comprising organotypic slices, was utilized to investigate the reaction of the innate immune system present in the nasal mucosa upon biofilm formation and treatment with 1,8-Cineol. Interestingly Staphylococcus epidermidis, the cause of very common catheter infections, possesses a biofilm generation pathway very similar to S. aureus and might be treatable in a similar fashion. The two presented in vitro model systems might be transferred to combinations of every biofilm forming bacterial with most kind of epithelium and mucosa.
Related Concept Videos
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...

